Prothena Corporation PLC (PRTA): Price to Earnings Adjusted for Growth Rate
Prothena Corporation (PRTA) is scaling its neurobiological developments through strategic alliances with pharmaceutical behemoths. Investments in a top-tier scientific staff enable the creation of unique drugs, as confirmed by the PEG ratio. The current value of 0.00 corresponds to the valuation metric relative to growth rates. Business dynamics rely on clinical trial cycles, minimizing the impact of general macroeconomic risks.
Metric breakdowns and analytics for Prothena (PRTA)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Capital Prothena Corporation|PRTA - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Prothena Corporation plc|PRTA - Company Aggregate Debts|Debts to Book Capitalization Prothena Corp|PRTA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Prothena|Quick Liquidity Indicator prothena.com
- earnings and market ratios statistics:
PRTA - Company Net Income|Expected Net Profit Prothena Corporation|PRTA - Price to Earnings Ratio|Future Price to Earnings Multiple Prothena Biosciences|PRTA - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Prothena Corp|PRTA - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Prothena|PRTA - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months prothena.com|PRTA - Earnings growth in current year|Earnings growth forecast for next year Prothena Corporation
General company analysis:PRTA Prothena Corp
Investors are assessing the resilience of Prothena Corporation (PRTA) through the P/E ratio relative to earnings growth rates, which helps determine the fairness of the market value in relation to business expansion. By analyzing the average PEG ratio, one can understand how effectively the outsourcing of production and trials converts into capitalization, where a metric below one signals an undervaluation of the amyloidosis therapy's potential.
Who Prothena Corporation competes with
BIIB (Biogen Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|Regencell Corp (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM: Price/Earnings to Growth Multiple|acadia-pharm.com - Company Value to Earnings Growth Ratio|XENE: PEG Multiple|Viking Therapeutics Inc - Growth-Adjusted Payback Ratio|SUPN (Supernus Pharma) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Catalyst Corp CPRX|Price/Earnings to Growth Ratio Denali Therapeutics (DNLI)|harmonybiosciences.com - Growth-Adjusted P/E Ratio|PEG Multiple BHVN (Biohaven)|PEG Multiple Amylyx Pharmaceuticals Inc AMLX|TRVI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Corp)|AVXL: PEG Multiple|Price/Earnings to Growth Multiple ceribell.com|Price/Earnings to Growth Ratio Alector Inc.|Price to Earnings Adjusted for Growth Rate Annexon Biosciences ANNX|Price/Earnings to Growth Ratio Omeros Corporation (OMER)|NGNE (Neurogene Therapeutics) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio AC Immune ACIU|VYGR (voyagertherapeutics.com) - Market Cap to Earnings and Growth Ratio|NMRA - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Scilex Holding|Tevogen Bio Holdings, Inc. (TVGN) - Price/Earnings to Growth Ratio|Alpha Cognition Inc. - Growth-Adjusted Payback Ratio|CGTX (Cognition Therapeutics) - PEG Multiple|PEG Multiple inhibikase.com|Price/Earnings to Growth Multiple SAVA (Cassava Sciences)|Company Value to Earnings Growth Ratio ASRT|PEG Multiple COYA (Coya Therapeutics)|Growth-Adjusted Market Cap to Net Income VistaGen Therapeutics, Inc. (VTGN)|OVID - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate acumenpharm.com|CervoMed (CRVO) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ATHE|Price/Earnings to Growth Ratio Clene Inc|PepGen Corp - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Jupiter Neurosciences Inc (JUNS)|RLMD (relmada.com) - Growth-Adjusted Payback Ratio|Annovis Bio - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio GRCE (Grace Therapeutics Inc)|Firefly Neuroscience Inc - PEG Multiple|KLTO - PEG Multiple|neurosense-tx.com (NRSN) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio RVPH|MTVA (MetaVia Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NeurAxis Inc. NRXS|Price/Earnings to Growth Multiple HSDT (Helius Medical)|PEG Multiple passagebio.com (PASG)|Price/Earnings to Growth Ratio Neuphoria Therapeutics NEUP|Growth-Adjusted Payback Ratio NERV|ATHA - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Addex Therapeutics Ltd.|alzamend.com (ALZN) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio CYCN (Cyclerion Therapeutics, Inc.)|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|KTTA: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Cortigent, Inc. (CRGT)|ATXI - Price to Earnings Adjusted for Growth Rate|Brainstorm Cell Therapeutics, Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio CARA (Cara Therapeutics Inc)|Chromocell Therapeutics - PEG Multiple|Growth-Adjusted Payback Ratio ELYM (Eliem Therapeutics)|ITCI: PEG Multiple|Price to Earnings Adjusted for Growth Rate Longboard Pharmaceuticals Inc (LBPH)|Price/Earnings to Growth Ratio Marinus|Growth-Adjusted P/E Ratio NKGN (NKGen Biotech Corp)|PEG Multiple NRBO|PEG Multiple sagerx.com (SAGE)|Synaptogenix - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio TRVN|Vigil Neuro - PEG Multiple|Anew Medical Inc. (WENA) - Price/Earnings to Growth Multiple|Cerevel Therapeutics (CERE) - Price/Earnings to Growth Ratio
